nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—Methotrexate—urinary bladder cancer	0.285	1	CrCtD
Pralatrexate—SLC19A1—urinary bladder cancer	0.195	0.775	CbGaD
Pralatrexate—SLC19A1—Methotrexate—urinary bladder cancer	0.0604	0.298	CbGbCtD
Pralatrexate—TYMS—urinary bladder cancer	0.0566	0.225	CbGaD
Pralatrexate—FPGS—Methotrexate—urinary bladder cancer	0.0437	0.216	CbGbCtD
Pralatrexate—Pemetrexed—Methotrexate—urinary bladder cancer	0.0377	0.2	CrCrCtD
Pralatrexate—Folic Acid—Methotrexate—urinary bladder cancer	0.0377	0.2	CrCrCtD
Pralatrexate—Leucovorin—Methotrexate—urinary bladder cancer	0.0377	0.2	CrCrCtD
Pralatrexate—Raltitrexed—Methotrexate—urinary bladder cancer	0.0377	0.2	CrCrCtD
Pralatrexate—Tetrahydrofolic acid—Methotrexate—urinary bladder cancer	0.0377	0.2	CrCrCtD
Pralatrexate—TYMS—Gemcitabine—urinary bladder cancer	0.0328	0.162	CbGbCtD
Pralatrexate—TYMS—Fluorouracil—urinary bladder cancer	0.028	0.138	CbGbCtD
Pralatrexate—DHFR—Methotrexate—urinary bladder cancer	0.0222	0.11	CbGbCtD
Pralatrexate—TYMS—Methotrexate—urinary bladder cancer	0.0155	0.0763	CbGbCtD
Pralatrexate—Renal failure chronic—Mitomycin—urinary bladder cancer	0.00178	0.0811	CcSEcCtD
Pralatrexate—SLC19A1—prostate gland—urinary bladder cancer	0.0017	0.129	CbGeAlD
Pralatrexate—FPGS—prostate gland—urinary bladder cancer	0.00113	0.0859	CbGeAlD
Pralatrexate—FPGS—seminal vesicle—urinary bladder cancer	0.00096	0.0726	CbGeAlD
Pralatrexate—SLC19A1—female reproductive system—urinary bladder cancer	0.00093	0.0704	CbGeAlD
Pralatrexate—FPGS—urethra—urinary bladder cancer	0.00076	0.0575	CbGeAlD
Pralatrexate—Renal failure chronic—Gemcitabine—urinary bladder cancer	0.000754	0.0343	CcSEcCtD
Pralatrexate—TYMS—prostate gland—urinary bladder cancer	0.000744	0.0563	CbGeAlD
Pralatrexate—DHFR—prostate gland—urinary bladder cancer	0.000737	0.0558	CbGeAlD
Pralatrexate—Renal failure chronic—Cisplatin—urinary bladder cancer	0.000703	0.032	CcSEcCtD
Pralatrexate—DHFR—seminal vesicle—urinary bladder cancer	0.000623	0.0472	CbGeAlD
Pralatrexate—FPGS—female reproductive system—urinary bladder cancer	0.000619	0.0469	CbGeAlD
Pralatrexate—FPGS—vagina—urinary bladder cancer	0.00056	0.0424	CbGeAlD
Pralatrexate—SLC19A1—lymph node—urinary bladder cancer	0.000544	0.0412	CbGeAlD
Pralatrexate—TYMS—smooth muscle tissue—urinary bladder cancer	0.000527	0.0399	CbGeAlD
Pralatrexate—DHFR—renal system—urinary bladder cancer	0.000502	0.038	CbGeAlD
Pralatrexate—DHFR—urethra—urinary bladder cancer	0.000493	0.0373	CbGeAlD
Pralatrexate—TYMS—female reproductive system—urinary bladder cancer	0.000406	0.0307	CbGeAlD
Pralatrexate—DHFR—female reproductive system—urinary bladder cancer	0.000402	0.0304	CbGeAlD
Pralatrexate—Methotrexate—SLC19A1—urinary bladder cancer	0.000398	0.235	CrCbGaD
Pralatrexate—TYMS—Podofilox—Etoposide—urinary bladder cancer	0.000392	0.713	CbGdCrCtD
Pralatrexate—Tumour lysis syndrome—Methotrexate—urinary bladder cancer	0.000374	0.017	CcSEcCtD
Pralatrexate—TYMS—vagina—urinary bladder cancer	0.000367	0.0278	CbGeAlD
Pralatrexate—DHFR—vagina—urinary bladder cancer	0.000364	0.0275	CbGeAlD
Pralatrexate—FPGS—lymph node—urinary bladder cancer	0.000362	0.0274	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Epirubicin—urinary bladder cancer	0.00035	0.0159	CcSEcCtD
Pralatrexate—Raltitrexed—TYMS—urinary bladder cancer	0.000346	0.204	CrCbGaD
Pralatrexate—Tumour lysis syndrome—Doxorubicin—urinary bladder cancer	0.000324	0.0147	CcSEcCtD
Pralatrexate—Back pain—Valrubicin—urinary bladder cancer	0.000295	0.0134	CcSEcCtD
Pralatrexate—Pancytopenia—Mitomycin—urinary bladder cancer	0.000286	0.013	CcSEcCtD
Pralatrexate—Neoplasm malignant—Thiotepa—urinary bladder cancer	0.000283	0.0129	CcSEcCtD
Pralatrexate—Anaemia—Valrubicin—urinary bladder cancer	0.000281	0.0128	CcSEcCtD
Pralatrexate—Leucovorin—TYMS—urinary bladder cancer	0.000262	0.155	CrCbGaD
Pralatrexate—Neoplasm malignant—Gemcitabine—urinary bladder cancer	0.000238	0.0108	CcSEcCtD
Pralatrexate—TYMS—lymph node—urinary bladder cancer	0.000238	0.018	CbGeAlD
Pralatrexate—DHFR—lymph node—urinary bladder cancer	0.000235	0.0178	CbGeAlD
Pralatrexate—Pemetrexed—TYMS—urinary bladder cancer	0.00021	0.124	CrCbGaD
Pralatrexate—Sepsis—Thiotepa—urinary bladder cancer	0.000209	0.00953	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.000203	0.00925	CcSEcCtD
Pralatrexate—Abdominal pain—Valrubicin—urinary bladder cancer	0.000196	0.00894	CcSEcCtD
Pralatrexate—Body temperature increased—Valrubicin—urinary bladder cancer	0.000196	0.00894	CcSEcCtD
Pralatrexate—Anaemia—Mitomycin—urinary bladder cancer	0.000194	0.00883	CcSEcCtD
Pralatrexate—Leukopenia—Mitomycin—urinary bladder cancer	0.000188	0.00855	CcSEcCtD
Pralatrexate—Cough—Mitomycin—urinary bladder cancer	0.000183	0.00833	CcSEcCtD
Pralatrexate—Body temperature increased—Carboplatin—urinary bladder cancer	0.000182	0.00828	CcSEcCtD
Pralatrexate—Asthenia—Valrubicin—urinary bladder cancer	0.000178	0.00812	CcSEcCtD
Pralatrexate—Sepsis—Gemcitabine—urinary bladder cancer	0.000176	0.00802	CcSEcCtD
Pralatrexate—Pruritus—Valrubicin—urinary bladder cancer	0.000176	0.00801	CcSEcCtD
Pralatrexate—Sepsis—Fluorouracil—urinary bladder cancer	0.000173	0.00789	CcSEcCtD
Pralatrexate—Oedema—Mitomycin—urinary bladder cancer	0.000171	0.00779	CcSEcCtD
Pralatrexate—Diarrhoea—Valrubicin—urinary bladder cancer	0.00017	0.00774	CcSEcCtD
Pralatrexate—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.000168	0.00763	CcSEcCtD
Pralatrexate—Anorexia—Mitomycin—urinary bladder cancer	0.000163	0.00743	CcSEcCtD
Pralatrexate—Dehydration—Thiotepa—urinary bladder cancer	0.000163	0.00742	CcSEcCtD
Pralatrexate—TYMS—Azacitidine—Gemcitabine—urinary bladder cancer	0.000158	0.287	CbGdCrCtD
Pralatrexate—Vomiting—Valrubicin—urinary bladder cancer	0.000158	0.00719	CcSEcCtD
Pralatrexate—Rash—Valrubicin—urinary bladder cancer	0.000157	0.00713	CcSEcCtD
Pralatrexate—Dermatitis—Valrubicin—urinary bladder cancer	0.000157	0.00713	CcSEcCtD
Pralatrexate—Dyspnoea—Mitomycin—urinary bladder cancer	0.000153	0.00695	CcSEcCtD
Pralatrexate—Sepsis—Etoposide—urinary bladder cancer	0.00015	0.00685	CcSEcCtD
Pralatrexate—Decreased appetite—Mitomycin—urinary bladder cancer	0.000149	0.00678	CcSEcCtD
Pralatrexate—Nausea—Valrubicin—urinary bladder cancer	0.000148	0.00672	CcSEcCtD
Pralatrexate—Fatigue—Mitomycin—urinary bladder cancer	0.000148	0.00672	CcSEcCtD
Pralatrexate—Pancytopenia—Thiotepa—urinary bladder cancer	0.000144	0.00655	CcSEcCtD
Pralatrexate—Liver function test abnormal—Gemcitabine—urinary bladder cancer	0.000136	0.00619	CcSEcCtD
Pralatrexate—Body temperature increased—Mitomycin—urinary bladder cancer	0.000135	0.00616	CcSEcCtD
Pralatrexate—Folic Acid—MTHFR—urinary bladder cancer	0.000134	0.0794	CrCbGaD
Pralatrexate—Tetrahydrofolic acid—MTHFR—urinary bladder cancer	0.000134	0.0794	CrCbGaD
Pralatrexate—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.000134	0.00611	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Gemcitabine—urinary bladder cancer	0.000133	0.00604	CcSEcCtD
Pralatrexate—Dehydration—Cisplatin—urinary bladder cancer	0.000128	0.00582	CcSEcCtD
Pralatrexate—Epistaxis—Thiotepa—urinary bladder cancer	0.000127	0.0058	CcSEcCtD
Pralatrexate—Hypokalaemia—Cisplatin—urinary bladder cancer	0.000125	0.00569	CcSEcCtD
Pralatrexate—Asthenia—Mitomycin—urinary bladder cancer	0.000123	0.00559	CcSEcCtD
Pralatrexate—Pancytopenia—Gemcitabine—urinary bladder cancer	0.000121	0.00551	CcSEcCtD
Pralatrexate—Neutropenia—Gemcitabine—urinary bladder cancer	0.000119	0.00542	CcSEcCtD
Pralatrexate—Pancytopenia—Fluorouracil—urinary bladder cancer	0.000119	0.00541	CcSEcCtD
Pralatrexate—Diarrhoea—Mitomycin—urinary bladder cancer	0.000117	0.00533	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.000116	0.0053	CcSEcCtD
Pralatrexate—Methotrexate—TYMS—urinary bladder cancer	0.000116	0.0683	CrCbGaD
Pralatrexate—Neoplasm malignant—Epirubicin—urinary bladder cancer	0.000114	0.00518	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.000113	0.00516	CcSEcCtD
Pralatrexate—Pancytopenia—Cisplatin—urinary bladder cancer	0.000113	0.00513	CcSEcCtD
Pralatrexate—Vomiting—Mitomycin—urinary bladder cancer	0.000109	0.00496	CcSEcCtD
Pralatrexate—Rash—Mitomycin—urinary bladder cancer	0.000108	0.00491	CcSEcCtD
Pralatrexate—Dermatitis—Mitomycin—urinary bladder cancer	0.000108	0.00491	CcSEcCtD
Pralatrexate—Epistaxis—Fluorouracil—urinary bladder cancer	0.000105	0.00479	CcSEcCtD
Pralatrexate—Neoplasm malignant—Doxorubicin—urinary bladder cancer	0.000105	0.00479	CcSEcCtD
Pralatrexate—Pancytopenia—Etoposide—urinary bladder cancer	0.000103	0.0047	CcSEcCtD
Pralatrexate—Back pain—Thiotepa—urinary bladder cancer	0.000102	0.00465	CcSEcCtD
Pralatrexate—Neutropenia—Etoposide—urinary bladder cancer	0.000102	0.00463	CcSEcCtD
Pralatrexate—Nausea—Mitomycin—urinary bladder cancer	0.000102	0.00463	CcSEcCtD
Pralatrexate—Anaemia—Thiotepa—urinary bladder cancer	9.75e-05	0.00444	CcSEcCtD
Pralatrexate—Leukopenia—Thiotepa—urinary bladder cancer	9.44e-05	0.0043	CcSEcCtD
Pralatrexate—Cough—Thiotepa—urinary bladder cancer	9.21e-05	0.00419	CcSEcCtD
Pralatrexate—Methotrexate—MTHFR—urinary bladder cancer	9.2e-05	0.0543	CrCbGaD
Pralatrexate—Sepsis—Methotrexate—urinary bladder cancer	9.01e-05	0.0041	CcSEcCtD
Pralatrexate—Back pain—Gemcitabine—urinary bladder cancer	8.58e-05	0.00391	CcSEcCtD
Pralatrexate—Sepsis—Epirubicin—urinary bladder cancer	8.43e-05	0.00384	CcSEcCtD
Pralatrexate—Thrombocytopenia—Thiotepa—urinary bladder cancer	8.43e-05	0.00384	CcSEcCtD
Pralatrexate—Tachycardia—Thiotepa—urinary bladder cancer	8.4e-05	0.00383	CcSEcCtD
Pralatrexate—Anorexia—Thiotepa—urinary bladder cancer	8.21e-05	0.00374	CcSEcCtD
Pralatrexate—Anaemia—Gemcitabine—urinary bladder cancer	8.2e-05	0.00373	CcSEcCtD
Pralatrexate—Anaemia—Fluorouracil—urinary bladder cancer	8.06e-05	0.00367	CcSEcCtD
Pralatrexate—Leukopenia—Gemcitabine—urinary bladder cancer	7.94e-05	0.00362	CcSEcCtD
Pralatrexate—Leukopenia—Fluorouracil—urinary bladder cancer	7.81e-05	0.00356	CcSEcCtD
Pralatrexate—Sepsis—Doxorubicin—urinary bladder cancer	7.8e-05	0.00355	CcSEcCtD
Pralatrexate—Cough—Gemcitabine—urinary bladder cancer	7.74e-05	0.00353	CcSEcCtD
Pralatrexate—Anaemia—Cisplatin—urinary bladder cancer	7.65e-05	0.00348	CcSEcCtD
Pralatrexate—Decreased appetite—Thiotepa—urinary bladder cancer	7.48e-05	0.00341	CcSEcCtD
Pralatrexate—Fatigue—Thiotepa—urinary bladder cancer	7.42e-05	0.00338	CcSEcCtD
Pralatrexate—Leukopenia—Cisplatin—urinary bladder cancer	7.4e-05	0.00337	CcSEcCtD
Pralatrexate—Constipation—Thiotepa—urinary bladder cancer	7.36e-05	0.00335	CcSEcCtD
Pralatrexate—Back pain—Etoposide—urinary bladder cancer	7.33e-05	0.00334	CcSEcCtD
Pralatrexate—Oedema—Gemcitabine—urinary bladder cancer	7.24e-05	0.0033	CcSEcCtD
Pralatrexate—Oedema—Fluorouracil—urinary bladder cancer	7.12e-05	0.00324	CcSEcCtD
Pralatrexate—Thrombocytopenia—Gemcitabine—urinary bladder cancer	7.09e-05	0.00323	CcSEcCtD
Pralatrexate—Pain in extremity—Epirubicin—urinary bladder cancer	7.05e-05	0.00321	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Thiotepa—urinary bladder cancer	7.04e-05	0.00321	CcSEcCtD
Pralatrexate—Anaemia—Etoposide—urinary bladder cancer	7e-05	0.00319	CcSEcCtD
Pralatrexate—Thrombocytopenia—Fluorouracil—urinary bladder cancer	6.97e-05	0.00317	CcSEcCtD
Pralatrexate—Liver function test abnormal—Methotrexate—urinary bladder cancer	6.96e-05	0.00317	CcSEcCtD
Pralatrexate—Tachycardia—Fluorouracil—urinary bladder cancer	6.95e-05	0.00316	CcSEcCtD
Pralatrexate—Anorexia—Gemcitabine—urinary bladder cancer	6.9e-05	0.00314	CcSEcCtD
Pralatrexate—Body temperature increased—Thiotepa—urinary bladder cancer	6.81e-05	0.0031	CcSEcCtD
Pralatrexate—Abdominal pain—Thiotepa—urinary bladder cancer	6.81e-05	0.0031	CcSEcCtD
Pralatrexate—Anorexia—Fluorouracil—urinary bladder cancer	6.79e-05	0.00309	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	6.79e-05	0.00309	CcSEcCtD
Pralatrexate—Leukopenia—Etoposide—urinary bladder cancer	6.78e-05	0.00309	CcSEcCtD
Pralatrexate—Oedema—Cisplatin—urinary bladder cancer	6.75e-05	0.00307	CcSEcCtD
Pralatrexate—Cough—Etoposide—urinary bladder cancer	6.61e-05	0.00301	CcSEcCtD
Pralatrexate—Thrombocytopenia—Cisplatin—urinary bladder cancer	6.61e-05	0.00301	CcSEcCtD
Pralatrexate—Tachycardia—Cisplatin—urinary bladder cancer	6.59e-05	0.003	CcSEcCtD
Pralatrexate—Dehydration—Epirubicin—urinary bladder cancer	6.56e-05	0.00299	CcSEcCtD
Pralatrexate—Pain in extremity—Doxorubicin—urinary bladder cancer	6.53e-05	0.00297	CcSEcCtD
Pralatrexate—Liver function test abnormal—Epirubicin—urinary bladder cancer	6.51e-05	0.00296	CcSEcCtD
Pralatrexate—Dyspnoea—Gemcitabine—urinary bladder cancer	6.46e-05	0.00294	CcSEcCtD
Pralatrexate—Anorexia—Cisplatin—urinary bladder cancer	6.44e-05	0.00293	CcSEcCtD
Pralatrexate—Hypokalaemia—Epirubicin—urinary bladder cancer	6.42e-05	0.00292	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	6.35e-05	0.00289	CcSEcCtD
Pralatrexate—Dyspnoea—Fluorouracil—urinary bladder cancer	6.35e-05	0.00289	CcSEcCtD
Pralatrexate—Decreased appetite—Gemcitabine—urinary bladder cancer	6.3e-05	0.00287	CcSEcCtD
Pralatrexate—Fatigue—Gemcitabine—urinary bladder cancer	6.24e-05	0.00284	CcSEcCtD
Pralatrexate—Constipation—Gemcitabine—urinary bladder cancer	6.19e-05	0.00282	CcSEcCtD
Pralatrexate—Decreased appetite—Fluorouracil—urinary bladder cancer	6.19e-05	0.00282	CcSEcCtD
Pralatrexate—Pancytopenia—Methotrexate—urinary bladder cancer	6.19e-05	0.00282	CcSEcCtD
Pralatrexate—Asthenia—Thiotepa—urinary bladder cancer	6.18e-05	0.00281	CcSEcCtD
Pralatrexate—Neutropenia—Methotrexate—urinary bladder cancer	6.09e-05	0.00277	CcSEcCtD
Pralatrexate—Pruritus—Thiotepa—urinary bladder cancer	6.09e-05	0.00277	CcSEcCtD
Pralatrexate—Dehydration—Doxorubicin—urinary bladder cancer	6.07e-05	0.00276	CcSEcCtD
Pralatrexate—Thrombocytopenia—Etoposide—urinary bladder cancer	6.06e-05	0.00276	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	6.05e-05	0.00276	CcSEcCtD
Pralatrexate—Tachycardia—Etoposide—urinary bladder cancer	6.04e-05	0.00275	CcSEcCtD
Pralatrexate—Liver function test abnormal—Doxorubicin—urinary bladder cancer	6.03e-05	0.00274	CcSEcCtD
Pralatrexate—Dyspnoea—Cisplatin—urinary bladder cancer	6.02e-05	0.00274	CcSEcCtD
Pralatrexate—Hypokalaemia—Doxorubicin—urinary bladder cancer	5.94e-05	0.0027	CcSEcCtD
Pralatrexate—Anorexia—Etoposide—urinary bladder cancer	5.9e-05	0.00268	CcSEcCtD
Pralatrexate—Diarrhoea—Thiotepa—urinary bladder cancer	5.89e-05	0.00268	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	5.88e-05	0.00268	CcSEcCtD
Pralatrexate—Decreased appetite—Cisplatin—urinary bladder cancer	5.87e-05	0.00267	CcSEcCtD
Pralatrexate—Pancytopenia—Epirubicin—urinary bladder cancer	5.79e-05	0.00264	CcSEcCtD
Pralatrexate—Body temperature increased—Gemcitabine—urinary bladder cancer	5.73e-05	0.00261	CcSEcCtD
Pralatrexate—Neutropenia—Epirubicin—urinary bladder cancer	5.7e-05	0.0026	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	5.67e-05	0.00258	CcSEcCtD
Pralatrexate—Body temperature increased—Fluorouracil—urinary bladder cancer	5.63e-05	0.00256	CcSEcCtD
Pralatrexate—Dyspnoea—Etoposide—urinary bladder cancer	5.51e-05	0.00251	CcSEcCtD
Pralatrexate—Epistaxis—Methotrexate—urinary bladder cancer	5.48e-05	0.00249	CcSEcCtD
Pralatrexate—Vomiting—Thiotepa—urinary bladder cancer	5.47e-05	0.00249	CcSEcCtD
Pralatrexate—Rash—Thiotepa—urinary bladder cancer	5.43e-05	0.00247	CcSEcCtD
Pralatrexate—Dermatitis—Thiotepa—urinary bladder cancer	5.42e-05	0.00247	CcSEcCtD
Pralatrexate—Decreased appetite—Etoposide—urinary bladder cancer	5.38e-05	0.00245	CcSEcCtD
Pralatrexate—Pancytopenia—Doxorubicin—urinary bladder cancer	5.36e-05	0.00244	CcSEcCtD
Pralatrexate—Body temperature increased—Cisplatin—urinary bladder cancer	5.34e-05	0.00243	CcSEcCtD
Pralatrexate—Fatigue—Etoposide—urinary bladder cancer	5.33e-05	0.00243	CcSEcCtD
Pralatrexate—Constipation—Etoposide—urinary bladder cancer	5.29e-05	0.00241	CcSEcCtD
Pralatrexate—Neutropenia—Doxorubicin—urinary bladder cancer	5.27e-05	0.0024	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	5.24e-05	0.00239	CcSEcCtD
Pralatrexate—Asthenia—Gemcitabine—urinary bladder cancer	5.2e-05	0.00237	CcSEcCtD
Pralatrexate—Epistaxis—Epirubicin—urinary bladder cancer	5.13e-05	0.00233	CcSEcCtD
Pralatrexate—Pruritus—Gemcitabine—urinary bladder cancer	5.12e-05	0.00233	CcSEcCtD
Pralatrexate—Nausea—Thiotepa—urinary bladder cancer	5.11e-05	0.00233	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Etoposide—urinary bladder cancer	5.06e-05	0.0023	CcSEcCtD
Pralatrexate—Pruritus—Fluorouracil—urinary bladder cancer	5.04e-05	0.00229	CcSEcCtD
Pralatrexate—Diarrhoea—Gemcitabine—urinary bladder cancer	4.96e-05	0.00226	CcSEcCtD
Pralatrexate—Abdominal pain—Etoposide—urinary bladder cancer	4.89e-05	0.00223	CcSEcCtD
Pralatrexate—Body temperature increased—Etoposide—urinary bladder cancer	4.89e-05	0.00223	CcSEcCtD
Pralatrexate—Diarrhoea—Fluorouracil—urinary bladder cancer	4.87e-05	0.00222	CcSEcCtD
Pralatrexate—Asthenia—Cisplatin—urinary bladder cancer	4.84e-05	0.00221	CcSEcCtD
Pralatrexate—Epistaxis—Doxorubicin—urinary bladder cancer	4.74e-05	0.00216	CcSEcCtD
Pralatrexate—Diarrhoea—Cisplatin—urinary bladder cancer	4.62e-05	0.0021	CcSEcCtD
Pralatrexate—Vomiting—Gemcitabine—urinary bladder cancer	4.61e-05	0.0021	CcSEcCtD
Pralatrexate—Rash—Gemcitabine—urinary bladder cancer	4.57e-05	0.00208	CcSEcCtD
Pralatrexate—Dermatitis—Gemcitabine—urinary bladder cancer	4.56e-05	0.00208	CcSEcCtD
Pralatrexate—Vomiting—Fluorouracil—urinary bladder cancer	4.53e-05	0.00206	CcSEcCtD
Pralatrexate—Rash—Fluorouracil—urinary bladder cancer	4.49e-05	0.00204	CcSEcCtD
Pralatrexate—Dermatitis—Fluorouracil—urinary bladder cancer	4.49e-05	0.00204	CcSEcCtD
Pralatrexate—Asthenia—Etoposide—urinary bladder cancer	4.44e-05	0.00202	CcSEcCtD
Pralatrexate—Back pain—Methotrexate—urinary bladder cancer	4.39e-05	0.002	CcSEcCtD
Pralatrexate—Pruritus—Etoposide—urinary bladder cancer	4.38e-05	0.00199	CcSEcCtD
Pralatrexate—Nausea—Gemcitabine—urinary bladder cancer	4.3e-05	0.00196	CcSEcCtD
Pralatrexate—Vomiting—Cisplatin—urinary bladder cancer	4.29e-05	0.00195	CcSEcCtD
Pralatrexate—Rash—Cisplatin—urinary bladder cancer	4.26e-05	0.00194	CcSEcCtD
Pralatrexate—Dermatitis—Cisplatin—urinary bladder cancer	4.25e-05	0.00194	CcSEcCtD
Pralatrexate—Diarrhoea—Etoposide—urinary bladder cancer	4.23e-05	0.00193	CcSEcCtD
Pralatrexate—Nausea—Fluorouracil—urinary bladder cancer	4.23e-05	0.00193	CcSEcCtD
Pralatrexate—Anaemia—Methotrexate—urinary bladder cancer	4.2e-05	0.00191	CcSEcCtD
Pralatrexate—Back pain—Epirubicin—urinary bladder cancer	4.11e-05	0.00187	CcSEcCtD
Pralatrexate—Leukopenia—Methotrexate—urinary bladder cancer	4.06e-05	0.00185	CcSEcCtD
Pralatrexate—Nausea—Cisplatin—urinary bladder cancer	4.01e-05	0.00183	CcSEcCtD
Pralatrexate—Cough—Methotrexate—urinary bladder cancer	3.96e-05	0.0018	CcSEcCtD
Pralatrexate—Vomiting—Etoposide—urinary bladder cancer	3.93e-05	0.00179	CcSEcCtD
Pralatrexate—Anaemia—Epirubicin—urinary bladder cancer	3.93e-05	0.00179	CcSEcCtD
Pralatrexate—Rash—Etoposide—urinary bladder cancer	3.9e-05	0.00178	CcSEcCtD
Pralatrexate—Dermatitis—Etoposide—urinary bladder cancer	3.9e-05	0.00177	CcSEcCtD
Pralatrexate—Leukopenia—Epirubicin—urinary bladder cancer	3.8e-05	0.00173	CcSEcCtD
Pralatrexate—Back pain—Doxorubicin—urinary bladder cancer	3.8e-05	0.00173	CcSEcCtD
Pralatrexate—Cough—Epirubicin—urinary bladder cancer	3.71e-05	0.00169	CcSEcCtD
Pralatrexate—FPGS—Metabolism—NAT2—urinary bladder cancer	3.69e-05	0.00104	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.67e-05	0.00104	CbGpPWpGaD
Pralatrexate—Nausea—Etoposide—urinary bladder cancer	3.67e-05	0.00167	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	3.67e-05	0.00104	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	3.67e-05	0.00104	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TNF—urinary bladder cancer	3.64e-05	0.00103	CbGpPWpGaD
Pralatrexate—Anaemia—Doxorubicin—urinary bladder cancer	3.63e-05	0.00165	CcSEcCtD
Pralatrexate—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.63e-05	0.00165	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—EP300—urinary bladder cancer	3.61e-05	0.00102	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—MYC—urinary bladder cancer	3.61e-05	0.00102	CbGpPWpGaD
Pralatrexate—Anorexia—Methotrexate—urinary bladder cancer	3.53e-05	0.00161	CcSEcCtD
Pralatrexate—Leukopenia—Doxorubicin—urinary bladder cancer	3.52e-05	0.0016	CcSEcCtD
Pralatrexate—FPGS—Disease—ENO2—urinary bladder cancer	3.52e-05	0.000996	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—JAG1—urinary bladder cancer	3.51e-05	0.000994	CbGpPWpGaD
Pralatrexate—Oedema—Epirubicin—urinary bladder cancer	3.47e-05	0.00158	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—ENO2—urinary bladder cancer	3.46e-05	0.000981	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—HPGDS—urinary bladder cancer	3.46e-05	0.000981	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	3.46e-05	0.000979	CbGpPWpGaD
Pralatrexate—Cough—Doxorubicin—urinary bladder cancer	3.43e-05	0.00156	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—NCOR1—urinary bladder cancer	3.42e-05	0.000969	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	3.41e-05	0.000965	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.39e-05	0.00155	CcSEcCtD
Pralatrexate—Tachycardia—Epirubicin—urinary bladder cancer	3.38e-05	0.00154	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—GSTT1—urinary bladder cancer	3.36e-05	0.000951	CbGpPWpGaD
Pralatrexate—DHFR—Disease—GSTO2—urinary bladder cancer	3.35e-05	0.00095	CbGpPWpGaD
Pralatrexate—FPGS—Disease—RBX1—urinary bladder cancer	3.34e-05	0.000944	CbGpPWpGaD
Pralatrexate—Anorexia—Epirubicin—urinary bladder cancer	3.3e-05	0.0015	CcSEcCtD
Pralatrexate—Dyspnoea—Methotrexate—urinary bladder cancer	3.3e-05	0.0015	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	3.3e-05	0.000933	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—STAG2—urinary bladder cancer	3.28e-05	0.000928	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—LIG1—urinary bladder cancer	3.28e-05	0.000928	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	3.25e-05	0.000921	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	3.23e-05	0.000914	CbGpPWpGaD
Pralatrexate—Decreased appetite—Methotrexate—urinary bladder cancer	3.22e-05	0.00147	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—TP53—urinary bladder cancer	3.21e-05	0.000909	CbGpPWpGaD
Pralatrexate—Oedema—Doxorubicin—urinary bladder cancer	3.21e-05	0.00146	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	3.2e-05	0.000905	CbGpPWpGaD
Pralatrexate—Fatigue—Methotrexate—urinary bladder cancer	3.19e-05	0.00145	CcSEcCtD
Pralatrexate—FPGS—Metabolism—RRM2—urinary bladder cancer	3.18e-05	0.0009	CbGpPWpGaD
Pralatrexate—DHFR—G1/S Transition—CDKN1A—urinary bladder cancer	3.16e-05	0.000893	CbGpPWpGaD
Pralatrexate—TYMS—E2F transcription factor network—MYC—urinary bladder cancer	3.15e-05	0.000891	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.14e-05	0.00143	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	3.13e-05	0.000887	CbGpPWpGaD
Pralatrexate—Tachycardia—Doxorubicin—urinary bladder cancer	3.13e-05	0.00143	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—RRM2—urinary bladder cancer	3.09e-05	0.000876	CbGpPWpGaD
Pralatrexate—Dyspnoea—Epirubicin—urinary bladder cancer	3.09e-05	0.00141	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—FAS—urinary bladder cancer	3.07e-05	0.000869	CbGpPWpGaD
Pralatrexate—Anorexia—Doxorubicin—urinary bladder cancer	3.06e-05	0.00139	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.03e-05	0.00138	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	3.02e-05	0.000854	CbGpPWpGaD
Pralatrexate—Decreased appetite—Epirubicin—urinary bladder cancer	3.01e-05	0.00137	CcSEcCtD
Pralatrexate—Fatigue—Epirubicin—urinary bladder cancer	2.99e-05	0.00136	CcSEcCtD
Pralatrexate—FPGS—Disease—JAG1—urinary bladder cancer	2.98e-05	0.000845	CbGpPWpGaD
Pralatrexate—Constipation—Epirubicin—urinary bladder cancer	2.96e-05	0.00135	CcSEcCtD
Pralatrexate—DHFR—Metabolism—GSTZ1—urinary bladder cancer	2.96e-05	0.000839	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ENO2—urinary bladder cancer	2.95e-05	0.000834	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—HPGDS—urinary bladder cancer	2.95e-05	0.000834	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	2.94e-05	0.000833	CbGpPWpGaD
Pralatrexate—Abdominal pain—Methotrexate—urinary bladder cancer	2.93e-05	0.00133	CcSEcCtD
Pralatrexate—Body temperature increased—Methotrexate—urinary bladder cancer	2.93e-05	0.00133	CcSEcCtD
Pralatrexate—Dyspnoea—Doxorubicin—urinary bladder cancer	2.86e-05	0.0013	CcSEcCtD
Pralatrexate—FPGS—Metabolism—GSTT1—urinary bladder cancer	2.86e-05	0.000809	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	2.84e-05	0.000804	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.83e-05	0.00129	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.83e-05	0.0008	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.81e-05	0.000797	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTO2—urinary bladder cancer	2.81e-05	0.000795	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NAT1—urinary bladder cancer	2.81e-05	0.000795	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.8e-05	0.000793	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—NQO1—urinary bladder cancer	2.79e-05	0.000791	CbGpPWpGaD
Pralatrexate—Decreased appetite—Doxorubicin—urinary bladder cancer	2.79e-05	0.00127	CcSEcCtD
Pralatrexate—Fatigue—Doxorubicin—urinary bladder cancer	2.77e-05	0.00126	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—CDKN1A—urinary bladder cancer	2.75e-05	0.000779	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	2.75e-05	0.000778	CbGpPWpGaD
Pralatrexate—Constipation—Doxorubicin—urinary bladder cancer	2.74e-05	0.00125	CcSEcCtD
Pralatrexate—Abdominal pain—Epirubicin—urinary bladder cancer	2.74e-05	0.00125	CcSEcCtD
Pralatrexate—Body temperature increased—Epirubicin—urinary bladder cancer	2.74e-05	0.00125	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	2.73e-05	0.000774	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—CDK4—urinary bladder cancer	2.7e-05	0.000765	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—RRM2—urinary bladder cancer	2.7e-05	0.000764	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	2.66e-05	0.000753	CbGpPWpGaD
Pralatrexate—Asthenia—Methotrexate—urinary bladder cancer	2.66e-05	0.00121	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—SMC1A—urinary bladder cancer	2.63e-05	0.000744	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.62e-05	0.00119	CcSEcCtD
Pralatrexate—Pruritus—Methotrexate—urinary bladder cancer	2.62e-05	0.00119	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—MYC—urinary bladder cancer	2.62e-05	0.000741	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SLC19A1—urinary bladder cancer	2.61e-05	0.000739	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTZ1—urinary bladder cancer	2.59e-05	0.000732	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	2.57e-05	0.000728	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—UGT2B7—urinary bladder cancer	2.57e-05	0.000727	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	2.57e-05	0.000727	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NCOR1—urinary bladder cancer	2.56e-05	0.000724	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PRSS3—urinary bladder cancer	2.54e-05	0.00072	CbGpPWpGaD
Pralatrexate—Abdominal pain—Doxorubicin—urinary bladder cancer	2.54e-05	0.00115	CcSEcCtD
Pralatrexate—Body temperature increased—Doxorubicin—urinary bladder cancer	2.54e-05	0.00115	CcSEcCtD
Pralatrexate—Diarrhoea—Methotrexate—urinary bladder cancer	2.53e-05	0.00115	CcSEcCtD
Pralatrexate—Asthenia—Epirubicin—urinary bladder cancer	2.49e-05	0.00113	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.46e-05	0.000695	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—PPARG—urinary bladder cancer	2.45e-05	0.000695	CbGpPWpGaD
Pralatrexate—Pruritus—Epirubicin—urinary bladder cancer	2.45e-05	0.00112	CcSEcCtD
Pralatrexate—TYMS—Metabolism—GSTO2—urinary bladder cancer	2.45e-05	0.000694	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NAT1—urinary bladder cancer	2.45e-05	0.000694	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HDAC4—urinary bladder cancer	2.43e-05	0.000687	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.43e-05	0.000687	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ERCC2—urinary bladder cancer	2.4e-05	0.00068	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	2.4e-05	0.000679	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—NQO1—urinary bladder cancer	2.37e-05	0.000672	CbGpPWpGaD
Pralatrexate—Diarrhoea—Epirubicin—urinary bladder cancer	2.37e-05	0.00108	CcSEcCtD
Pralatrexate—Vomiting—Methotrexate—urinary bladder cancer	2.36e-05	0.00107	CcSEcCtD
Pralatrexate—Rash—Methotrexate—urinary bladder cancer	2.34e-05	0.00106	CcSEcCtD
Pralatrexate—Dermatitis—Methotrexate—urinary bladder cancer	2.33e-05	0.00106	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—GSTP1—urinary bladder cancer	2.33e-05	0.000659	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	2.32e-05	0.000657	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP4B1—urinary bladder cancer	2.31e-05	0.000655	CbGpPWpGaD
Pralatrexate—Asthenia—Doxorubicin—urinary bladder cancer	2.3e-05	0.00105	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—SMC1A—urinary bladder cancer	2.29e-05	0.00065	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—MYC—urinary bladder cancer	2.28e-05	0.000646	CbGpPWpGaD
Pralatrexate—Pruritus—Doxorubicin—urinary bladder cancer	2.27e-05	0.00103	CcSEcCtD
Pralatrexate—SLC19A1—Disease—MTHFR—urinary bladder cancer	2.26e-05	0.000639	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TERT—urinary bladder cancer	2.25e-05	0.000638	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	2.25e-05	0.000636	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—UGT2B7—urinary bladder cancer	2.24e-05	0.000635	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	2.21e-05	0.000624	CbGpPWpGaD
Pralatrexate—Vomiting—Epirubicin—urinary bladder cancer	2.2e-05	0.001	CcSEcCtD
Pralatrexate—Nausea—Methotrexate—urinary bladder cancer	2.2e-05	0.001	CcSEcCtD
Pralatrexate—Diarrhoea—Doxorubicin—urinary bladder cancer	2.19e-05	0.000999	CcSEcCtD
Pralatrexate—Rash—Epirubicin—urinary bladder cancer	2.19e-05	0.000995	CcSEcCtD
Pralatrexate—DHFR—Metabolism—SLC19A1—urinary bladder cancer	2.19e-05	0.000619	CbGpPWpGaD
Pralatrexate—Dermatitis—Epirubicin—urinary bladder cancer	2.18e-05	0.000994	CcSEcCtD
Pralatrexate—FPGS—Disease—NCOR1—urinary bladder cancer	2.17e-05	0.000615	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—TYMS—urinary bladder cancer	2.17e-05	0.000613	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—GSTM1—urinary bladder cancer	2.14e-05	0.000606	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—NCOR1—urinary bladder cancer	2.14e-05	0.000606	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PRSS3—urinary bladder cancer	2.13e-05	0.000603	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—FGFR3—urinary bladder cancer	2.07e-05	0.000585	CbGpPWpGaD
Pralatrexate—Nausea—Epirubicin—urinary bladder cancer	2.06e-05	0.000938	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.06e-05	0.000582	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—GPX1—urinary bladder cancer	2.05e-05	0.00058	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERCC2—urinary bladder cancer	2.04e-05	0.000578	CbGpPWpGaD
Pralatrexate—Vomiting—Doxorubicin—urinary bladder cancer	2.04e-05	0.000929	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	2.04e-05	0.000577	CbGpPWpGaD
Pralatrexate—Rash—Doxorubicin—urinary bladder cancer	2.02e-05	0.000921	CcSEcCtD
Pralatrexate—Dermatitis—Doxorubicin—urinary bladder cancer	2.02e-05	0.00092	CcSEcCtD
Pralatrexate—TYMS—Metabolism—CYP4B1—urinary bladder cancer	2.02e-05	0.000571	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ERCC2—urinary bladder cancer	2.01e-05	0.00057	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.01e-05	0.000569	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	2e-05	0.000567	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GSTP1—urinary bladder cancer	1.98e-05	0.000561	CbGpPWpGaD
Pralatrexate—DHFR—Disease—LIG1—urinary bladder cancer	1.93e-05	0.000545	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	1.92e-05	0.000545	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MTHFR—urinary bladder cancer	1.92e-05	0.000544	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TERT—urinary bladder cancer	1.92e-05	0.000542	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC19A1—urinary bladder cancer	1.91e-05	0.00054	CbGpPWpGaD
Pralatrexate—Nausea—Doxorubicin—urinary bladder cancer	1.91e-05	0.000868	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—MTHFR—urinary bladder cancer	1.89e-05	0.000536	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PRSS3—urinary bladder cancer	1.86e-05	0.000526	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—TYMS—urinary bladder cancer	1.84e-05	0.000521	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCNE1—urinary bladder cancer	1.82e-05	0.000516	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GSTM1—urinary bladder cancer	1.82e-05	0.000515	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—NCOR1—urinary bladder cancer	1.82e-05	0.000515	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.82e-05	0.000514	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TYMS—urinary bladder cancer	1.79e-05	0.000507	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	1.78e-05	0.000504	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CREBBP—urinary bladder cancer	1.76e-05	0.000498	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.76e-05	0.000498	CbGpPWpGaD
Pralatrexate—FPGS—Disease—FGFR3—urinary bladder cancer	1.76e-05	0.000498	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.75e-05	0.000496	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GPX1—urinary bladder cancer	1.74e-05	0.000493	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ERCC2—urinary bladder cancer	1.71e-05	0.000484	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TYMP—urinary bladder cancer	1.7e-05	0.000482	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—PTEN—urinary bladder cancer	1.68e-05	0.000477	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.67e-05	0.000473	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.63e-05	0.00046	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—MTHFR—urinary bladder cancer	1.61e-05	0.000455	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—EP300—urinary bladder cancer	1.61e-05	0.000455	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—RHOA—urinary bladder cancer	1.59e-05	0.000451	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCNE1—urinary bladder cancer	1.59e-05	0.00045	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.56e-05	0.000442	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TERT—urinary bladder cancer	1.56e-05	0.000441	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NAT2—urinary bladder cancer	1.54e-05	0.000436	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PPARG—urinary bladder cancer	1.53e-05	0.000434	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CREBBP—urinary bladder cancer	1.5e-05	0.000424	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—TYMP—urinary bladder cancer	1.49e-05	0.00042	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CREBBP—urinary bladder cancer	1.47e-05	0.000417	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ERBB2—urinary bladder cancer	1.47e-05	0.000417	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ENO2—urinary bladder cancer	1.47e-05	0.000416	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.46e-05	0.000413	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTGS2—urinary bladder cancer	1.44e-05	0.000408	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.43e-05	0.000404	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—ATM—urinary bladder cancer	1.4e-05	0.000397	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDK4—urinary bladder cancer	1.4e-05	0.000395	CbGpPWpGaD
Pralatrexate—DHFR—Disease—RBX1—urinary bladder cancer	1.39e-05	0.000394	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.36e-05	0.000386	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TERT—urinary bladder cancer	1.36e-05	0.000385	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.36e-05	0.000384	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—RB1—urinary bladder cancer	1.36e-05	0.000384	CbGpPWpGaD
Pralatrexate—FPGS—Disease—RHOA—urinary bladder cancer	1.35e-05	0.000383	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.35e-05	0.000381	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NAT2—urinary bladder cancer	1.34e-05	0.00038	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—RRM2—urinary bladder cancer	1.33e-05	0.000376	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PPARG—urinary bladder cancer	1.3e-05	0.000369	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CDKN1A—urinary bladder cancer	1.26e-05	0.000357	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTEN—urinary bladder cancer	1.26e-05	0.000356	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CREBBP—urinary bladder cancer	1.25e-05	0.000355	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERBB2—urinary bladder cancer	1.25e-05	0.000355	CbGpPWpGaD
Pralatrexate—DHFR—Disease—JAG1—urinary bladder cancer	1.25e-05	0.000353	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—HPGDS—urinary bladder cancer	1.23e-05	0.000348	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ENO2—urinary bladder cancer	1.23e-05	0.000348	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTGS2—urinary bladder cancer	1.23e-05	0.000347	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—ATM—urinary bladder cancer	1.22e-05	0.000346	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDK4—urinary bladder cancer	1.22e-05	0.000345	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—RB1—urinary bladder cancer	1.21e-05	0.000344	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS2—urinary bladder cancer	1.21e-05	0.000342	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EP300—urinary bladder cancer	1.2e-05	0.000339	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.2e-05	0.000339	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTT1—urinary bladder cancer	1.19e-05	0.000338	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	1.19e-05	0.000338	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—RB1—urinary bladder cancer	1.18e-05	0.000335	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—SRC—urinary bladder cancer	1.17e-05	0.00033	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—RRM2—urinary bladder cancer	1.16e-05	0.000328	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—urinary bladder cancer	1.15e-05	0.000325	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—HPGDS—urinary bladder cancer	1.07e-05	0.000304	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ENO2—urinary bladder cancer	1.07e-05	0.000304	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CDKN1A—urinary bladder cancer	1.07e-05	0.000303	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTEN—urinary bladder cancer	1.07e-05	0.000302	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN2A—urinary bladder cancer	1.07e-05	0.000302	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—RB1—urinary bladder cancer	1.06e-05	0.0003	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTEN—urinary bladder cancer	1.05e-05	0.000298	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—urinary bladder cancer	1.04e-05	0.000296	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTT1—urinary bladder cancer	1.04e-05	0.000295	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	1.04e-05	0.000295	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTGS2—urinary bladder cancer	1.03e-05	0.00029	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EGFR—urinary bladder cancer	1.02e-05	0.000289	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EP300—urinary bladder cancer	1.02e-05	0.000288	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.01e-05	0.000285	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—EP300—urinary bladder cancer	1e-05	0.000284	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NQO1—urinary bladder cancer	9.92e-06	0.000281	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SRC—urinary bladder cancer	9.91e-06	0.000281	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	9.75e-06	0.000276	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KRAS—urinary bladder cancer	9.65e-06	0.000273	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN2A—urinary bladder cancer	9.31e-06	0.000264	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—EP300—urinary bladder cancer	9.28e-06	0.000263	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NCOR1—urinary bladder cancer	9.08e-06	0.000257	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCND1—urinary bladder cancer	9.01e-06	0.000255	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTEN—urinary bladder cancer	8.95e-06	0.000253	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—urinary bladder cancer	8.88e-06	0.000251	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	8.8e-06	0.000249	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN1A—urinary bladder cancer	8.72e-06	0.000247	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EGFR—urinary bladder cancer	8.69e-06	0.000246	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NQO1—urinary bladder cancer	8.66e-06	0.000245	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERCC2—urinary bladder cancer	8.54e-06	0.000242	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—EP300—urinary bladder cancer	8.53e-06	0.000242	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	8.51e-06	0.000241	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—EP300—urinary bladder cancer	8.3e-06	0.000235	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTP1—urinary bladder cancer	8.27e-06	0.000234	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KRAS—urinary bladder cancer	8.21e-06	0.000232	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HRAS—urinary bladder cancer	8.2e-06	0.000232	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—EP300—urinary bladder cancer	8.1e-06	0.000229	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—urinary bladder cancer	8.09e-06	0.000229	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MTHFR—urinary bladder cancer	8.02e-06	0.000227	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TERT—urinary bladder cancer	8e-06	0.000226	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCND1—urinary bladder cancer	7.87e-06	0.000223	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TYMS—urinary bladder cancer	7.69e-06	0.000218	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN1A—urinary bladder cancer	7.61e-06	0.000215	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTM1—urinary bladder cancer	7.6e-06	0.000215	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NCOR1—urinary bladder cancer	7.6e-06	0.000215	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FGFR3—urinary bladder cancer	7.34e-06	0.000208	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GPX1—urinary bladder cancer	7.28e-06	0.000206	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—EP300—urinary bladder cancer	7.24e-06	0.000205	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—urinary bladder cancer	7.23e-06	0.000205	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTP1—urinary bladder cancer	7.22e-06	0.000204	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ERCC2—urinary bladder cancer	7.15e-06	0.000202	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—urinary bladder cancer	7.06e-06	0.0002	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HRAS—urinary bladder cancer	6.97e-06	0.000197	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—MTHFR—urinary bladder cancer	6.72e-06	0.00019	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NCOR1—urinary bladder cancer	6.63e-06	0.000188	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTM1—urinary bladder cancer	6.63e-06	0.000188	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GPX1—urinary bladder cancer	6.35e-06	0.00018	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—urinary bladder cancer	6.31e-06	0.000179	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CREBBP—urinary bladder cancer	6.25e-06	0.000177	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ERCC2—urinary bladder cancer	6.24e-06	0.000177	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—urinary bladder cancer	5.94e-06	0.000168	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—MTHFR—urinary bladder cancer	5.86e-06	0.000166	CbGpPWpGaD
Pralatrexate—DHFR—Disease—RHOA—urinary bladder cancer	5.65e-06	0.00016	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PPARG—urinary bladder cancer	5.45e-06	0.000154	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CREBBP—urinary bladder cancer	5.23e-06	0.000148	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERBB2—urinary bladder cancer	5.23e-06	0.000148	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—urinary bladder cancer	5.18e-06	0.000147	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTGS2—urinary bladder cancer	5.12e-06	0.000145	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PPARG—urinary bladder cancer	4.75e-06	0.000135	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CREBBP—urinary bladder cancer	4.57e-06	0.000129	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CDKN1A—urinary bladder cancer	4.47e-06	0.000127	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTEN—urinary bladder cancer	4.46e-06	0.000126	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS2—urinary bladder cancer	4.29e-06	0.000121	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EP300—urinary bladder cancer	4.26e-06	0.00012	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SRC—urinary bladder cancer	4.14e-06	0.000117	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS2—urinary bladder cancer	3.74e-06	0.000106	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTEN—urinary bladder cancer	3.74e-06	0.000106	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—urinary bladder cancer	3.71e-06	0.000105	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGFR—urinary bladder cancer	3.63e-06	0.000103	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—EP300—urinary bladder cancer	3.57e-06	0.000101	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KRAS—urinary bladder cancer	3.43e-06	9.7e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTEN—urinary bladder cancer	3.26e-06	9.23e-05	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—EP300—urinary bladder cancer	3.11e-06	8.81e-05	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HRAS—urinary bladder cancer	2.91e-06	8.25e-05	CbGpPWpGaD
